THERANOSTICS 2016*
Chairs: Rod Hicks & Jason Lewis
Sponsored by:
Optimised production of 64Cu-SARTATE for a phase 1 clinical trial (#4)
11:00 AM
68Ga, 64Cu labelling and affinity study of NODAGANOC, a NODAGA conjugated somatostatin analogue (#5)
11:15 AM
Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE (#6)
11:30 AM
DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy (PRRT) patients with personalised high activities (#7)
11:45 AM